thalidomide has been researched along with Immunologic Deficiency Syndromes in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Immunologic Deficiency Syndromes: Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Periodic fever was controlled in the first month after adalimumab therapy and IVIG replacement, but recurred in the second month." | 5.91 | Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). ( Deng, M; Han, T; Li, Y; Mao, H; Mo, W, 2023) |
| "MDS with trisomy 8 has been observed in adult patients with Behçet syndrome with some cases developing prior to the clinical manifestations of the latter." | 2.44 | Myelodysplastic syndrome with trisomy 8 associated with Behçet syndrome: an immunologic link to a karyotypic abnormality. ( Bolton-Maggs, P; Field, A; Moots, R; Salim, R; Thachil, JV, 2008) |
| "Periodic fever was controlled in the first month after adalimumab therapy and IVIG replacement, but recurred in the second month." | 1.91 | Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). ( Deng, M; Han, T; Li, Y; Mao, H; Mo, W, 2023) |
| "Treatment with lenalidomide increased RhoA activity and reversed the migration and activation defects of RASGRP1-deficient lymphocytes." | 1.43 | RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. ( Ban, SA; Banerjee, PP; Bennett, KL; Bilic, I; Boztug, K; Cagdas, D; Dupré, L; Garncarz, W; Gribben, JG; Hons, M; Hsu, HT; Huppa, JB; Jäger, U; Mace, EM; McClanahan, F; Mukherjee, M; Orange, JS; Petronczki, ÖY; Pfajfer, L; Pickl, WF; Platzer, R; Salzer, E; Sanal, Ö; Sinha, P; Sixt, M; Stockinger, H; Supper, V; Tezcan, I; Willmann, KL; Zlabinger, GJ, 2016) |
| "Thalidomide has already been proven to differentially regulate immune responses and support anti-apoptosis in immunodeficiency syndromes." | 1.39 | Thalidomide has anti-inflammatory properties in neonatal immune cells. ( Faust, K; Härtel, C; Puzik, A; Thiel, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dev, A | 1 |
| Sil, A | 1 |
| Jindal, AK | 1 |
| Tyagi, R | 1 |
| Rawat, A | 1 |
| Vinay, K | 1 |
| Li, Y | 1 |
| Deng, M | 1 |
| Han, T | 1 |
| Mo, W | 1 |
| Mao, H | 1 |
| Salzer, E | 1 |
| Cagdas, D | 1 |
| Hons, M | 1 |
| Mace, EM | 1 |
| Garncarz, W | 1 |
| Petronczki, ÖY | 1 |
| Platzer, R | 1 |
| Pfajfer, L | 1 |
| Bilic, I | 1 |
| Ban, SA | 1 |
| Willmann, KL | 1 |
| Mukherjee, M | 1 |
| Supper, V | 1 |
| Hsu, HT | 1 |
| Banerjee, PP | 1 |
| Sinha, P | 1 |
| McClanahan, F | 1 |
| Zlabinger, GJ | 1 |
| Pickl, WF | 1 |
| Gribben, JG | 1 |
| Stockinger, H | 1 |
| Bennett, KL | 1 |
| Huppa, JB | 1 |
| Dupré, L | 1 |
| Sanal, Ö | 1 |
| Jäger, U | 1 |
| Sixt, M | 1 |
| Tezcan, I | 1 |
| Orange, JS | 1 |
| Boztug, K | 1 |
| Puzik, A | 1 |
| Thiel, A | 1 |
| Faust, K | 1 |
| Härtel, C | 1 |
| Thachil, JV | 1 |
| Salim, R | 1 |
| Field, A | 1 |
| Moots, R | 1 |
| Bolton-Maggs, P | 1 |
1 review available for thalidomide and Immunologic Deficiency Syndromes
| Article | Year |
|---|---|
Myelodysplastic syndrome with trisomy 8 associated with Behçet syndrome: an immunologic link to a karyotypic abnormality.
Topics: Adolescent; Anemia, Refractory; Behcet Syndrome; Chromosomes, Human, Pair 8; Female; Humans; Immunol | 2008 |
4 other studies available for thalidomide and Immunologic Deficiency Syndromes
| Article | Year |
|---|---|
Cutaneous involvement in DOCK8-related immunodeficiency syndrome responding to thalidomide.
Topics: Guanine Nucleotide Exchange Factors; Humans; Immunologic Deficiency Syndromes; Thalidomide | 2022 |
Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD).
Topics: Adalimumab; Anemia, Sideroblastic; Female; Fever; Humans; Immunoglobulins, Intravenous; Immunologic | 2023 |
RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics.
Topics: Actins; Adolescent; Angiogenesis Inhibitors; B-Lymphocytes; Cell Movement; Cell Proliferation; Child | 2016 |
Thalidomide has anti-inflammatory properties in neonatal immune cells.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blood Cells; Cell Separation; Cells, Cult | 2013 |